Search Results - "Natrajan, Kavita"

FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma by Natrajan, Kavita, Kaushal, Megha, George, Bindu, Kanapuru, Bindu, Theoret, Marc R

“…In February 2022, the U.S. Food and Drug Administration approved ciltacabtagene autoleucel, a chimeric antigen receptor (CAR) T cell therapy targeting the…”
Get full text

Bilateral nonpitting edema and xerotic skin by Joglekar, Kiran, Jackson, Christopher, Natrajan, Kavita, Usatine, Richard P

Get full text

A successful model to decrease early deaths in acute promyelocytic leukemia (APL) through the use of a simplified algorithm and expert support by Jillella, Anand P., Kolhe, Ravindra B., Natrajan, Kavita, Kota, Vamsi

“…Abstract only…”
Get full text

Bilateral nonpitting edema and xerotic skin by Joglekar, Kiran, Jackson, Christopher, Natrajan, Kavita

“…When treatment for cellulitis and a suspected exacerbation of congestive heart failure failed, we ordered a biopsy. The pathology report made the diagnosis…”
Get full text

Characteristics and Potential Biomarkers for Chronic Pain in Patients with Sickle Cell Disease by Kuei, Nina, Patel, Niren, Xu, Hongyan, Wells, Leigh, Bowman, Latanya, Bora, Pritam, Natrajan, Kavita, Kutlar, Abdullah

“…Vaso-occlusive episodes (VOE) or pain crises are a hallmark of sickle cell disease (SCD), with increasing recognition that a significant portion of SCD…”
Get full text

Detection of Pulmonary Platelet Thrombi in Acute Chest Syndrome in Sickle Cell Disease: Novel Findings in an Autopsy Case Series by Anea, Ciprian, Adeyemi, Amidat, Lee, Itia, Natrajan, Kavita, Falls, Greer, Kutlar, Abdullah, Brittain, Julia E.

“…Introduction: Acute chest syndrome (ACS) is one of the leading causes of death in patients with sickle cell disease (SCD). The pulmonary manifestations of ACS…”
Get full text

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts by Talpaz, Moshe, Paquette, Ronald, Afrin, Lawrence, Hamburg, Solomon I, Prchal, Josef T, Jamieson, Katarzyna, Terebelo, Howard R, Ortega, Gregory L, Lyons, Roger M, Tiu, Ramon V, Winton, Elliott F, Natrajan, Kavita, Odenike, Olatoyosi, Claxton, David, Peng, Wei, O'Neill, Peter, Erickson-Viitanen, Susan, Leopold, Lance, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Verstovsek, Srdan

“…Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in…”
Get full text

Plasma Biomarkers of Iron Regulation, Overload, and Inflammation in Sickle Cell Disease by Mangaonkar, Abhishek, Patel, Niren, Xu, Hongyan, Natrajan, Kavita, Clair, Betsy, Wells, Leigh G, Bowman, Latanya, Barret, Nadine, Kutlar, Abdullah

“…Transfusional iron overload has been increasingly recognized among patients with sickle cell disease (SCD) over the past two decades. We recently reported on…”
Get full text

Pivotal Role Of Heat Shock Proteins In Monocyte and Endothelial Cell Pathology In Sickle Cell Disease by Umapathy, Nagavedi S., Natrajan, Kavita, Kutlar, Abdullah, Meiler, Steffen E., Brittain, Julia E.

“…It is well established that sickle cell disease (SCD) manifests global perturbations of hemostasis. Vaso-occlusion, inflammation and coagulopathy all likely…”
Get full text

A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US by Jillella, Anand P., Kolhe, Ravindra B., Awan, Farrukh, Natrajan, Kavita, Kota, Vamsi

“…APL is a highly curable malignancy with reported survival above 90% in many large co-operative group studies. The most recent GIMEMA trial in low and…”
Get full text

Genetic Association Studies of Pain Phenotypes in Adult SCD Patients by Kutlar, Abdullah, Wells, Leigh G, Xu, Hongyan, Bowman, Latanya, Bora, Pritam, Chand, Arati Rani, Clair, Betsy, Meiler, Steffen E, Wang, Xiaoling, Natrajan, Kavita, Patel, Niren, Fillingim, Roger B

“…Vasoocclusive episodes (VOEs) are the hallmark of sickle cell disease (SCD) responsible for > 90% of health care utilization. Several studies have elucidated…”
Get full text

Are There True Non-Responders to Hydroxyurea in Sickle Cell Disease? a Multiparameter Analysis by Chand, Arati Rani, Xu, Hongyan, Wells, Leigh G, Clair, Betsy, Neunert, Cindy, Spellman, Alison E, Clay, Leila Jerome, Natrajan, Kavita, Kutlar, Abdullah

“…Hydroxyurea (HU) is the only FDA approved anti-switching agent for the management of sickle cell disease (SCD). The non-response rate to HU (inadequate…”
Get full text

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent by Kutlar, Abdullah, Swerdlow, Paul S., Meiler, Steffen E., Natrajan, Kavita, Wells, Leigh G, Clair, Betsy, Shah, Sheetal, Knight, Robert

“…Thalidomide (THAL), lenalidomide (LEN), and pomalidomide (POM) have been used successfully in the treatment of several inflammatory and neoplastic disorders…”
Get full text

A simple but effective model to decrease early deaths in acute promyelocytic leukemia (APL) by Jillella, Anand P., Sadek, Ibrahim, Morrison, Devi, Natrajan, Kavita, Awan, Farrukh Tauseef, Kolhe, Ravindra, Kota, Vamsi

“…Abstract only 6573 Background: Recent reports suggest that approximately 30% of patients with APL die during induction. This has been confirmed in large…”
Get full text

miRNA expression profiling of CD20+ plasma cell myeloma (PCM): Upregulation of miR-155 shedding new insight into disease biology and clinicopathologic behavior by Kolhe, Ravindra, Jillella, Anand P., Natrajan, Kavita, Awan, Farrukh Tauseef, Manaloor, Elizabeth, Kota, Vamsi

“…Abstract only 8108 Background: Up to15-20% of patients with PCM have expression of CD20, although the significance of this remains unclear. The prognostic…”
Get full text

Long Term Outcome of Patients Enrolled Into STOP and STOP II Trials: A Single Center Experience by Sayer, Gloria, Bowman, Latanya, Clair, Betsy, Cail, Austin, Blanchard, Beverly, Natrajan, Kavita, McKie, Virgil, Adams, Robert J., Kutlar, Abdullah

“…Abstract ▪3219▪This icon denotes a clinically relevant abstract The landmark STOP trial established chronic transfusion as an effective therapeutic modality…”
Get full text

Retrospective Analysis of Core Decompression in Avascular Necrosis of the Femoral Head in Patients with Sickle Cell Disease by Cail, Austin, Natrajan, Kavita, Barrett, Nadine, Bowman, Latanya, Clair, Betsy, Sayer, Gloria, Isales, Carlos, Corpe, Raymond Scott, Kutlar, Abdullah

“…Abstract 2108▪▪This icon denotes a clinically relevant abstract Avascular necrosis (AVN) of the femoral head is a common complication of sickle cell disease…”
Get full text

Allogeneic Transplantation Following Reduced Intensity Conditioning with Fludarabine and Melphalan In Patients with Advanced Myelofibrosis Is Associated with Unacceptable Rates of Acute Graft-Vs-Host Disease and Non-Relapse Mortality by Kochuparambil, Samith Thomas, Natrajan, Kavita, Jillella, Anand P., Hamadani, Sayed Mehdi, Awan, Farrukh

“…Abstract 4552 Allogeneic hematopoietic stem cell transplant (HSCT) offers a potentially curative option for patients with primary myelofibrosis (PMF). The…”
Get full text

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts by Talpaz, Moshe, Paquette, Ronald, Afrin, Lawrence, Hamburg, Solomon, Jamieson, Katarzyna, Terebelo, Howard, Ortega, Gregory, Lyons, Roger M., Tiu, Ramon V., Winton, Elliott F., Natrajan, Kavita, Odenike, Olatoyosi, Peng, Wei, Sandor, Victor A., O'Neill, Peter, Erickson-Viitanen, Sue, Leopold, Lance, Levy, Richard S, Kantarjian, Hagop M, Verstovsek, Srdan

“…Abstract 176▪▪This icon denotes a clinically relevant abstract Ruxolitinib (RUX) has demonstrated clinical benefit for patients with myelofibrosis (MF) with or…”
Get full text